MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
MIMEDX (NASDAQ:MDXG) has announced a strategic collaboration with Vaporox, establishing co-promotion and co-marketing of MIMEDX's placental allograft portfolio alongside Vaporox's Vaporous Hyperoxia Therapy (VHT) device. The partnership includes a strategic investment by MIMEDX in Vaporox and exclusive rights for potential acquisition discussions.
Vaporox's FDA-cleared VHT device combines ultrasonic mist and concentrated oxygen to treat nine types of chronic wounds, including Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers. Clinical studies have shown wound healing rates exceeding 80% at 20 weeks when VHT is combined with standard wound care, with promising results when used with MIMEDX's EPIFIX® products.
MIMEDX (NASDAQ:MDXG) ha annunciato una collaborazione strategica con Vaporox, avviando una co-promozione e co-marketing del portfolio di allograft placentari di MIMEDX insieme al dispositivo Vaporous Hyperoxia Therapy (VHT) di Vaporox. La partnership prevede un investimento strategico di MIMEDX in Vaporox e diritti esclusivi per eventuali trattative di acquisizione.
Il dispositivo VHT di Vaporox, approvato dalla FDA, combina nebbia ultrasonica e ossigeno concentrato per trattare nove tipi di ferite croniche, tra cui ulcere del piede diabetico, ulcere venose alle gambe e piaghe da decubito. Studi clinici hanno dimostrato tassi di guarigione delle ferite superiori all'80% a 20 settimane quando il VHT viene utilizzato insieme alle cure standard per le ferite, con risultati promettenti anche in combinazione con i prodotti EPIFIX® di MIMEDX.
MIMEDX (NASDAQ:MDXG) ha anunciado una colaboración estratégica con Vaporox, estableciendo una copromoción y comarketing del portafolio de aloinjertos placentarios de MIMEDX junto con el dispositivo Vaporous Hyperoxia Therapy (VHT) de Vaporox. La asociación incluye una inversión estratégica de MIMEDX en Vaporox y derechos exclusivos para posibles negociaciones de adquisición.
El dispositivo VHT de Vaporox, aprobado por la FDA, combina niebla ultrasónica y oxígeno concentrado para tratar nueve tipos de heridas crónicas, incluyendo úlceras del pie diabético, úlceras venosas en las piernas y úlceras por presión. Estudios clínicos han demostrado tasas de curación de heridas superiores al 80% a las 20 semanas cuando VHT se combina con el cuidado estándar de heridas, con resultados prometedores al usarse junto con los productos EPIFIX® de MIMEDX.
MIMEDX (NASDAQ:MDXG)는 Vaporox와 전략적 협력을 발표하며 MIMEDX의 태반 동종이식편 포트폴리오와 Vaporox의 Vaporous Hyperoxia Therapy (VHT) 장치의 공동 프로모션 및 공동 마케팅을 시작했습니다. 이번 파트너십에는 MIMEDX의 Vaporox에 대한 전략적 투자와 잠재적 인수 논의를 위한 독점 권리가 포함되어 있습니다.
Vaporox의 FDA 승인 VHT 장치는 초음파 미스트와 농축 산소를 결합하여 당뇨병성 족부 궤양, 정맥성 하지 궤양, 욕창 등 9가지 만성 상처를 치료합니다. 임상 연구에 따르면 VHT를 표준 상처 관리와 병행했을 때 20주 후 상처 치유율이 80% 이상에 달하며, MIMEDX의 EPIFIX® 제품과 함께 사용 시에도 유망한 결과를 보였습니다.
MIMEDX (NASDAQ:MDXG) a annoncé une collaboration stratégique avec Vaporox, établissant une copromotion et un comarketing du portefeuille d'allogreffes placentaires de MIMEDX aux côtés du dispositif Vaporous Hyperoxia Therapy (VHT) de Vaporox. Le partenariat inclut un investissement stratégique de MIMEDX dans Vaporox ainsi que des droits exclusifs pour d'éventuelles discussions d'acquisition.
Le dispositif VHT de Vaporox, approuvé par la FDA, combine brume ultrasonique et oxygène concentré pour traiter neuf types de plaies chroniques, notamment les ulcères du pied diabétique, les ulcères veineux des jambes et les escarres. Des études cliniques ont montré des taux de cicatrisation supérieurs à 80 % à 20 semaines lorsque le VHT est associé aux soins standards des plaies, avec des résultats prometteurs lorsqu'il est utilisé avec les produits EPIFIX® de MIMEDX.
MIMEDX (NASDAQ:MDXG) hat eine strategische Zusammenarbeit mit Vaporox angekündigt, bei der die gemeinsame Vermarktung und Bewerbung des placentalen Allograft-Portfolios von MIMEDX zusammen mit dem Vaporous Hyperoxia Therapy (VHT)-Gerät von Vaporox erfolgt. Die Partnerschaft umfasst eine strategische Investition von MIMEDX in Vaporox sowie exklusive Rechte für mögliche Übernahmegespräche.
Das von der FDA zugelassene VHT-Gerät von Vaporox kombiniert ultraschallnebel und konzentrierten Sauerstoff, um neun Arten chronischer Wunden zu behandeln, darunter diabetische Fußgeschwüre, venöse Beingeschwüre und Druckgeschwüre. Klinische Studien zeigten Wundheilungsraten von über 80 % nach 20 Wochen, wenn VHT mit der Standard-Wundversorgung kombiniert wird, mit vielversprechenden Ergebnissen bei der Anwendung zusammen mit den EPIFIX®-Produkten von MIMEDX.
- Strategic investment and exclusive acquisition rights in Vaporox strengthen MIMEDX's market position
- VHT device has FDA 510(k) clearance for treating nine types of wounds
- Clinical studies show over 80% wound healing rates at 20 weeks
- Complementary technology shows promising results with MIMEDX's EPIFIX products
- Partnership expands MIMEDX's portfolio diversification in wound care
- Financial terms and investment amount not disclosed
- Market penetration timeline and revenue impact unclear
Insights
MIMEDX's strategic Vaporox partnership expands wound care offerings with complementary technology and potential acquisition rights.
MIMEDX's collaboration with Vaporox represents a calculated expansion into the chronic wound care market. The partnership combines MIMEDX's established placental allograft portfolio with Vaporox's FDA-cleared Vaporous Hyperoxia Therapy (VHT) device, creating a more comprehensive wound care solution. The VHT technology delivers a dual therapeutic approach—ultrasonic mist and concentrated oxygen—and is cleared to treat nine wound types including Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers.
Particularly noteworthy is MIMEDX's financial investment in Vaporox and securing of exclusivity rights for potential acquisition discussions. This suggests a long-term strategic interest beyond mere co-marketing, potentially signaling future integration of Vaporox's technology into MIMEDX's portfolio. The clinical validation of VHT is compelling, with three IRB studies showing wound healing rates exceeding 80% at 20 weeks when combined with standard care.
The synergistic potential between these technologies is significant, as the press release mentions promising real-world efficacy when VHT is used alongside MIMEDX's EPIFIX® product. This complementary relationship could create stronger market differentiation in the competitive wound care space. For MIMEDX, this collaboration addresses its stated strategic goal of portfolio diversification while providing access to an adjacent technology without the immediate full cost of acquisition. The partnership structure allows both companies to leverage their respective strengths while potentially setting the stage for deeper integration based on market performance.
Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions.
Vaporox is a privately held, Denver-based company that has developed and is commercializing its patented Vaporous Hyperoxia Therapy (“VHT”) device for treating chronic and hard-to-heal wounds. VHT delivers two healing modalities, ultrasonic mist and concentrated oxygen, in a single device and has received a 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to treat nine types of wounds, including Diabetic Foot Ulcers (“DFUs”), Venous Leg Ulcers (“VLUs”) and Pressure Ulcers (bed sores).
“We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox,” commented Joseph H. Capper, MIMEDX Chief Executive Officer. “Together with our leading placental allografts, VHT will offer clinicians across numerous care settings another proven option to treat chronic, hard-to-heal wounds. We view this as a highly complementary addition that will help us grow in this important setting, where patients with difficult wounds often begin their recovery.”
“Vaporox is excited to partner with a market leader in wound care to expand awareness and adoption of our technology,” said Alan Sage, Chief Executive Officer of Vaporox. “We believe co-promotion with MIMEDX will accelerate our market penetration and create a synergistic offering—allowing us to reach more patients with these highly complementary offerings.”
VHT has been the subject of three IRB clinical studies, each of which demonstrated wound healing rates exceeding
About Vaporox, Inc.
Vaporox’s technology represents a breakthrough in treating chronic wounds. The company is focused on superior healing outcomes while reducing costs across a wide range of healthcare settings. With strong clinical results and growing adoption, Vaporox empowers providers to restore hope and healing for patients suffering from chronic wounds.
For additional information, please visit https://www.vaporox.com/.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
What is the strategic collaboration between MIMEDX (NASDAQ:MDXG) and Vaporox?
What is Vaporox's VHT device and what conditions does it treat?
What are the clinical results of Vaporox's VHT therapy?
How does the Vaporox VHT device complement MIMEDX's EPIFIX products?
What are the financial terms of MIMEDX's investment in Vaporox?
